ZS Pharma Announces Proposed Public Offering of Common

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
ZS Pharma Announces Proposed Public Offering of Common Stock

REDWOOD CITY, Calif., March 23, 2015 (GLOBE NEWSWIRE) -- ZS Pharma, Inc. (Nasdaq: ZSPH ), a biopharmaceutical company focused on the development and commercialization of highly selective, non-absorbed drugs to treat renal, cardiovascular, liver and metabolic disorders, today announced that it intends to offer and sell, subject to market and other conditions 3,300,000 shares of its common stock in an underwritten public offering. A single selling stockholder, Alta Partners VIII, L.P., expects to grant the underwriters a 30-day option to purchase up to 495,000 additional shares of the Company's common stock.

J.P. Morgan Securities LLC and Credit Suisse Securities (USA) LLC are acting as joint book- running managers for the offering. BMO Capital Markets Corp. is acting as lead manager and William Blair & Company, L.L.C. and LifeSci Capital LLC are acting as co-managers.

The Company currently expects to use the net proceeds from the offering to complete its ongoing long-term safety trial, ZS005; complete its ongoing long-term extension study, ZS004e; fund continuing scale-up of its active pharmaceutical ingredient, or API, manufacturing capacity; fund build-up of product inventory and launch quantities of ZS-9; and build a sales and marketing organization, including a sales force, to support commercial sales of ZS-9 in the United States, if approved.

The securities are being offered only by means of a prospectus. A preliminary prospectus, when available, may be obtained from J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (866) 803-9204, or by emailing prospectus-eq_fi@jpmchase.com ; or Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, One Madison Avenue, New York, NY 10010, by telephone at (800) 221-1037, or by email at newyork.prospectus@credit-suisse.com .

A registration statement relating to these securities has been filed with the Securities and Exchange Commission, but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About ZS Pharma

ZS Pharma is a publicly-traded (Nasdaq: ZSPH ), biopharmaceutical company with offices in Redwood City, California and Coppell, Texas. ZS Pharma's lead therapeutic candidate, ZS-9 (sodium zirconium cyclosilicate), is an investigational treatment for hyperkalemia that is being evaluated in late-stage clinical trials to demonstrate its ability to safely and effectively remove excess potassium from the blood and maintain normal potassium levels. ZS Pharma is also pursuing the discovery of additional drug candidates that utilize its novel selective ion-trap technology for the treatment of kidney and liver diseases.

Forward-Looking Statements

ZS Pharma cautions you that this press release contains forward-looking statements, including statements related to this offering and our intended use of the proceeds of this offering, that involve risks and uncertainties. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "aim," "anticipate," "assume," "believe," "contemplate," "continue," "could," "due," "estimate," "expect," "goal," "intend," "may," "objective," "plan," "predict," "potential," "positioned," "seek," "should," "target," "will," "would" and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. These forward-looking statements include, but are not limited to, statements about: our expectations regarding the timing of submitting an NDA to the FDA and MAA to the EMA and the likelihood of regulatory approval of ZS-9, our expectations regarding our ability to successfully commercialize ZS-9, if approved, estimates of our expenses, future revenue, capital requirements and needs for additional financing, our ability to produce ZS-9 in commercial quantities in higher capacity reactors, the initiation, timing, progress and results of future nonclinical studies, clinical trials and research and development programs, and our financial performance. Any forward looking statements in this press release are based on management's current expectations, estimates, forecasts, and projections about our business and the industry in which we operate and management's beliefs and assumptions are not guarantees of future performance or development and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control. As a result, any or all of our forward-looking statements in this press release may turn out to be inaccurate, including that securities of ZS Pharma, Inc. may not ultimately be offered to the public because of general market conditions or other factors. Factors that may cause actual results to differ materially from these expectations include, among other things, those listed under the heading "Risk Factors" in our Registration Statement on Form S-1 filed with the Securities and Exchange Commission on March 23, 2015 (File No. 333-202745), which is available on the SEC's website at http://www.sec.gov . All forward‐looking statements are qualified in their entirety by this cautionary statement and speak only as of the date of this press release. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.

ZS Pharma Contacts Adam Tomasi (Investors) ZS Pharma 650.458.4100 Denise Powell (Media) Red House Consulting 510.703.9491

Scroll down for more posts ▼

Top 10 Most Recent News Articles

University of Phoenix Poll Gets a Useful Reality Check

Updated Category News Views 108

Good Numbers, With the Usual Fine Print Employer approval is the kind of evidence career-focused schools desperately need, and University of Phoenix just put up a pretty loud batch of it. Among managers who directly supervise its graduates, 94% said the university understands employer needs, while 92% said its programs align with workforce demands. Those are stout...

Continue Reading
Tampa General's Food Bet Earns a 2026 Innovation Award

Updated Category News Views 78

Hospital meals have long been the punchline nobody bothered to fix, which is why Tampa General Hospital's latest recognition deserves a closer look. The not-for-profit academic health system was named the 2026 Inno Pick by the Tampa Bay Business Journal for its Food as Medicine initiative, its fifth straight year landing among the publication's Inno Award honorees. Awards...

Continue Reading
Alibaba Lawsuit Deadline Puts Disclosure Risk in Focus

Updated Category News Views 159

A calendar deadline is doing more work than any earnings headline for Alibaba shareholders this week. A securities class action notice says investors who bought or acquired Alibaba Group Holding Limited securities between May 23, 2024 and November 11, 2026 may seek appointment as lead plaintiff by January 19, 2027. That is a procedural milestone, not a verdict, and...

Continue Reading
Cottage Grove Tests Holiday Demand Across Lake Norman

Updated Category News Views 125

Flour and foot traffic make a pretty honest little scoreboard. Cottage Grove Bakery is putting itself in front of Lake Norman shoppers twice on Saturday, November 21, while also taking Thanksgiving orders and laying groundwork for 2027 workplace and school visits. This is not a public-company earnings story, and nobody should pretend a tray of scones is a quarterly...

Continue Reading
Domino's Probe Puts Franchise Disclosure Under Lens

Updated Category News Views 110

A franchisee's shuttered stores can turn cheerful unit-growth talk into a nasty accounting of credibility, and that is the uncomfortable territory Domino's now occupies. Kahn Swick & Foti has opened an investigation into whether Domino's officers and directors breached fiduciary duties or violated state or federal law. That is not a finding of misconduct. It is a legal...

Continue Reading
Payoneer Gets OCC Nod, but the Finish Line Is Ahead

Updated Category News Views 121

Federal bank paperwork is not usually thrilling, yet Payoneer just found a potentially meaningful lever for its cross-border payments machine. The company received preliminary conditional approval from the Office of the Comptroller of the Currency to form PAYO Digital Bank, a national trust bank intended to support stablecoin services. That is a real regulatory milestone...

Continue Reading
ASA’s 2026 Grants Push Dermatology Into New Terrain

Updated Category News Views 104

Thirteen Small Bets With Serious Human Stakes Skin science rarely gets the splashy headlines, yet it touches a staggering number of people and carries some very stubborn unanswered questions. American Skin Association’s 2026 grant class puts 13 awards across skin cancer and dermatologic disease, with a noticeable willingness to follow newer clinical terrain rather than...

Continue Reading
Surf City Seasons Put Vacation Rental Timing in Focus

Updated Category News Views 42

Summer’s Calendar Does the Talking School bells, not seagulls, appear to set the pace for Surf City’s rental market. Chris Rackley’s seasonal guide makes a pretty grounded point: the “best” time to visit Surf City, North Carolina, is not some universal magic week on a postcard. It depends on whether a traveler needs peak beach weather, wants elbow room, or...

Continue Reading
TEN Holdings Raises $1.0 Million as Dilution Looms

Updated Category News Views 66

A Small Raise With a Loud Message Nothing says “we need room to breathe” quite like selling 1,492,500 new shares for $0.67 apiece. TEN Holdings closed a roughly $1.0 million gross equity offering on November 20, 2026, and investors in NASDAQ:XHLD ought to look at this for what it is: a modest cash infusion that comes with immediate dilution. The company gets capital;...

Continue Reading
Tessera Delisting Leaves HLSQ in a Tougher Market Ahead

Updated Category News Views 116

November delivered a nasty little truth serum for Tessera Defense and Homeland Security: exchange status is not a cosmetic detail when the stock’s selling price has collapsed. On November 10, NYSE Regulation suspended trading in the company’s common shares on NYSE American and began delisting proceedings. By November 17, Tessera had a chance to request review by the...

Continue Reading

Top 5 Most Recently Viewed Articles

Major Settlement Proposed for TD Mutual Fund Class Action Cases

Updated Category News Views 65

Understanding the TD Mutual Fund Class Action Settlement If you have ever held units of a TD Mutual Fund through a discount broker, you may be part of a significant class action settlement that has recently come to light. TD Asset Management Inc. has agreed to a settlement amounting to C$70.25 million aimed at resolving claims on behalf of individuals who have held units...

Continue Reading
The No-Nonsense Breakdown on Church & Dwight Co. Stocks

Updated Category News Views 192

Church & Dwight Co: The Lay of the Land Let’s be real. Church & Dwight Co Inc. (NYSE:CHD) is on the radar, trading at about $103.08, and it just popped a neat 1.46%. However, look a little deeper, and you see it’s been a rocky ride over the past year with a drop of 5.41%. Basically, it’s like gearing up for a race—only to find out you’re running on a rocky...

Continue Reading
Experience the Excitement of Jaialdi at Fairfield Inn & Suites

Updated Category News Views 256

Welcoming Guests to the Jaialdi Festival Fairfield Inn & Suites Boise West is thrilled to welcome visitors for the upcoming Jaialdi Festival, an extraordinary event that celebrates Basque culture and tradition. This festival is held once every five years and is expected to gather attendees from around the globe to participate in the festivities. The hotel, operated by...

Continue Reading
Viridien's Successful Senior Secured Notes Offering Explained

Updated Category News Views 137

Success in Senior Secured Notes Offering Today marked a significant achievement for Viridien S.A. as the company announced the successful pricing of its offering of US$450 million 10% senior secured notes and €475 million 8.5% senior secured notes, both maturing in 2030. This offering signals a strong confidence in Viridien's financial strategy and operational...

Continue Reading
Legal Insights: Investors of Ready Capital Corporation (RC) Act Now

Updated Category News Views 133

Understanding the Situation with Ready Capital Corporation (RC) As an investor in Ready Capital Corporation, it's essential to stay informed about recent developments regarding the company, especially if you've faced any financial losses. Currently, there's an important deadline approaching that could affect shareholders significantly. Key Dates and Details for Investors...

Continue Reading